New Panel Expands Prenatal Genetic Screening

The UNITY Fetal Risk Screen now assesses 14 prevalent and actionable recessive and X-linked conditions, an expansion from its original 5-gene panel. This includes the five conditions recommended for screening in every pregnancy by the American College of Obstetricians and Gynecologists (ACOG), plus nine others common in Ashkenazi Jewish and pan-ethnic populations. The test can be performed as early as nine weeks into a pregnancy using a single maternal blood sample. This screening tool utilizes Quantitative Counting Template (QCT) technology to analyze cell-free DNA from the fetus found in the mother's bloodstream. Unlike traditional carrier screenings that provide a generic reproductive risk, the UNITY screen delivers a precise, pregnancy-specific fetal risk assessment, ranging from as low as 1 in 5,000 to as high as 9 in 10. This direct analysis of fetal DNA eliminates the need for a partner's sample, removing logistical delays and simplifying the testing workflow. Early detection of these conditions can be transformative for families, allowing them to connect with specialists and plan for potential treatments or interventions, such as gene therapies and dietary modifications, months earlier than with conventional methods. The panel screens for conditions like cystic fibrosis, spinal muscular atrophy, sickle cell disease, and Tay-Sachs disease. The expansion of such panels aims to address health disparities in prenatal care. Historically, genetic tests have been less accurate for non-white families due to a lack of diversity in the genomic data used to develop them. By including conditions relevant to more diverse populations, the expanded panel seeks to provide more equitable and actionable prenatal screening.